Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
National Institutes of Health · Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853)
Опубликован 4 мая 2026 г. · Осталось 33 дня
Простыми словами
Краткое описание на русском пока недоступно; показано на английском.
The US National Institutes of Health funds clinical trial sites in the United States that are testing investigational drugs or biologics for amyotrophic lateral sclerosis in intermediate patient populations not eligible for ongoing trials. Applications from US government agencies, universities, nonprofits, and private companies are due by 10 November 2026, but foreign organisations cannot apply.
Автоматическое краткое изложение текста донора; оригинальная формулировка приведена ниже.
Краткое описание
Исходный текст донора (английский)
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.
Фрагмент со страницы донора. Полный текст, приложения и формы — в исходном объявлении о конкурсе.
Кто может подать заявку
- Государственный орган
- Академическое или исследовательское учреждение
- НКО / гражданское общество
- Частная компания
Требования и условия
Показать требования из источника · Исходный текст донора (английский)
Applicant types: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; Others (see text field entitled "Additional Information on Eligibility" for clarification); Small businesses; County governments; Native American tribal governments (Federally recognized); State governments; Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; City or township governments; For profit organizations other than small businesses; Private institutions of higher education; Special district governments; Native American tribal organizations (other than Federally recognized tribal governments)
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Eligible applicants must be clinical trial sites that participate in a phase 2/3 or phase 3 efficacy clinical trial (designed to provide pivotal data to support a marketing application) supported by a small business concern that is the FDA-designated sponsor of a drug or biological product which is the subject of an IND under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) to prevent, diagnose, mitigate, treat, or cure ALS. The definition of a small business concern can be found in section 3(a) of the Small Business Act (15 U.S.C. 632(a)).Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.